Ana Arance
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Biological Psychiatry top 1%
Papers in
- Oncology 119
- Cancer Immunotherapy and Biomarkers 76
- CAR-T cell therapy research 56
- Cutaneous Melanoma Detection and Management 26
- Colorectal Cancer Treatments and Studies 12
-
- Melanoma and MAPK Pathways 86
- Co-authors
- Caroline Robert (48 shared papers)Jean‐Jacques Grob (40 shared papers)Georgina V. Long (49 shared papers)James Larkin (33 shared papers)Omid Hamid (19 shared papers)Matteo S. Carlino (21 shared papers)Reinhard Dummer (31 shared papers)Laurent Mortier (26 shared papers)
- Journals
- Journal of Clinical Oncology (55 papers)Annals of Oncology (23 papers)European Journal of Cancer (10 papers)Cancer Research (9 papers)The Lancet Oncology (7 papers)
- Partner nations
- SpainUnited StatesFrance
In The Last Decade
Ana Arance
153 papers receiving 8.6k citations
Ana Arance's Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 5.1k
- Biological Psychiatry 242
- Immunology 1.8k
- Cancer Research 862
- Molecular Biology 3.6k
Countries citing papers authored by Ana Arance
This map shows the geographic impact of Ana Arance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Arance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Arance more than expected).
Fields of papers citing papers by Ana Arance
This network shows the impact of papers produced by Ana Arance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Arance. The network helps show where Ana Arance may publish in the future.
Co-authors
The 25 scholars most cited alongside Ana Arance, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 167 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 931 |
| 2 | Clinical implications of the intrinsic molecular subtypes of breast cancer Hit paper breakdown → | 2015 | 800 |
| 3 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 798 |
| 4 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Hit paper breakdown → | 2019 | 735 |
| 5 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 706 |
| 6 | Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial Hit paper breakdown → | 2017 | 513 |
| 7 | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2018 | 413 |
| 8 | 2017 | 286 | |
| 9 | 2014 | 206 | |
| 10 | 2016 | 182 | |
| 11 | 2021 | 141 | |
| 12 | 2013 | 134 | |
| 13 | 2021 | 131 | |
| 14 | 2020 | 125 | |
| 15 | 2021 | 120 | |
| 16 | 2022 | 120 | |
| 17 | 2015 | 116 | |
| 18 | 2018 | 102 | |
| 19 | 2000 | 95 | |
| 20 | 2003 | 94 |
About Ana Arance
Ana Arance is a scholar working on Oncology, Molecular Biology, Immunology, Organic Chemistry and Pulmonary and Respiratory Medicine, having authored 167 papers that have together received 8.7k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (86 papers), Cancer Immunotherapy and Biomarkers (76 papers), CAR-T cell therapy research (56 papers), Cutaneous Melanoma Detection and Management (26 papers), Immunotherapy and Immune Responses (21 papers), Colorectal Cancer Treatments and Studies (12 papers), Click Chemistry and Applications (10 papers) and Brain Metastases and Treatment (6 papers). The work is most often cited by research in Oncology (5.1k citations), Biological Psychiatry (242 citations), Immunology (1.8k citations), Cancer Research (862 citations) and Molecular Biology (3.6k citations). Ana Arance has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Caroline Robert, Jean‐Jacques Grob, Georgina V. Long, James Larkin, Omid Hamid, Matteo S. Carlino, Reinhard Dummer, Laurent Mortier, Jacob Schachter and Paul Lorigan. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.